Organic Active Ingredients TRIZ Cases

A bioerodible pellet delivers pharmacologically active agents through controlled erosion and dissolution.

Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds inhibit type III receptor tyrosine kinases.

Gellan gum forms an in-situ gel that maintains therapeutic cobalamin levels for seven days, improving patient compliance.

Engineered T cells express PSMA-targeting CARs alongside dominant negative receptors to bypass immunosuppressive tumor signals.

Selective V1aR antagonists treat traumatic brain injury by reducing cerebral edema while avoiding cardiovascular side effects from peripheral receptor blockade.

Bifunctional SyAM-P compounds bind prostate-specific membrane antigen and modulate FcγRI receptors to stimulate immune responses.

A composition of Morus, Scutellaria, and Acacia extracts promotes bone density and protects cartilage integrity.

A floating gastroretentive dosage form utilizes a permeable elastic membrane to maintain mechanical integrity during gastric retention.

Rugged double-stranded RNA activates Toll-like receptor 3 via a stable structure that resists hydrolysis and reduces toxicity.

Covalent bonding with cysteine C481 provides reliable inhibition, overcoming limitations of reversible therapies for autoimmune and cancer treatments.

Light-curable hemostatic paste prevents low-viscosity flow away from the application site by hardening upon demand to maintain positioning.

Dual-site binding to the catalytic ATP and αD sites enhances selectivity over other kinases.

Optogenetic tools replace electrical stimulation to achieve millisecond temporal precision in controlling nervous system outputs.

Potassium chloride salts stabilize aqueous vitamin E against microbial growth without preservatives, avoiding acid hydrolysis and aseptic packaging costs.

Chemical synthesis of oligonucleotide aptamers replaces complex antibody production, lowering costs and eliminating cold chain requirements.

Escalating histamine dosing regimens selectively activate specific receptors to restore biological balance while minimizing side effects from uniform treatment.

Variable domains direct cytotoxic particles to P2X7-expressing cancer cells, reducing healthy tissue toxicity.

Merges antiandrogens with polo-like kinase inhibitors to overcome castrate-resistant prostate cancer progression.

Allosteric benzamide derivatives bind the conserved myristoyl pocket of BCR-ABL1, bypassing ATP-site mutations like T315I that block standard inhibitors.

Light activation of a photosensitizing agent releases antigens into the cytosol, bypassing lysosomal degradation to stimulate CD8 T-cell responses.

Merging immunomodulators with lubricants alleviates dry eye symptoms without stinging, reducing treatment complexity.

A segmented implantable device with a nanochannel membrane sustains intratumoral drug concentrations while preventing systemic toxicity from chemotherapy.

Compound 1 treats multiple HCV genotypes via NS5A inhibition, eliminating the need for pre-screening and reducing side effects.

Enzymatic treatment liberates lipids from biomass, preventing degradation and oxidation caused by high temperature spray drying.

Formula I compounds target MTHFD1 and MTHFD2 isoforms via segmentation and local quality principles, reducing side effects from non-specific enzyme inhibition.

A structured surfactant system suspends pharmaceutical actives using a sugar ester and fatty acid mixture.

Specific crystalline polymorphs maintain stable composition during storage, preventing amorphous conversion that degrades bioavailability.

4-Ethynylpyridine derivatives inhibit GCN2 kinase activity with high potency and excellent solubility for cancer treatment.

Myricetin derivatives replace synthetic agents to reverse dandruff gene expression while ensuring safety for pregnant women.

Crystalline oxime ether solid forms improve pharmaceutical compound stability for autoimmune disease treatments.

Combining Lactobacillus casei and Bifidobacterium breve with galactooligosaccharides activates tumor immunity.

One-chain cationic lipids shift to inverted hexagonal phases in endosomes, resolving stability versus delivery efficiency trade-offs.

Controlled crystallization yields stable form B, resolving polymorphic unpredictability to enhance spatial memory treatment in cognitive impairment models.

Specific piperidyl substituents resolve Tankyrase inhibition efficacy and specificity trade-offs.

Daily estetrol and drospirenone administration achieves a Pearl Index below five in women with high body mass index.

Compound A induces apoptosis in FLT3-ITD and MyD88 L265P mutant cancer cells, addressing insufficient treatment effectiveness and relapse risks.

Ethanol cosolvents stabilize high-concentration dexketoprofen and tramadol injections, preventing precipitation while maintaining therapeutic efficacy.

Niosomal encapsulation improves pharmacokinetic properties and anticancer efficacy by overcoming poor solubility and off-target toxicity.

Tyrosine in the lens releases dopamine to delay myopia progression without causing eye irritation.

Combining trastuzumab-MCC-DM1 with chemotherapy addresses HER2-positive breast cancer resistance by attacking tumor cells via multiple simultaneous pathways.

Initial intravenous lipid nanoparticle administration induces immune tolerance, enabling sustained protein expression during subsequent non-intravenous dosing.

Spray drying tetrandrine di-hydrochloride yields high-purity salts that resolve content uniformity issues in tablet manufacturing.

Analyzing diagnostic samples for RECQL mutations identifies five-fold increased risk, resolving inadequate susceptibility gene detection beyond BRCA1 and BRCA2.

A biodegradable hydrogel insert delivers glucocorticoids via diffusion and erosion mechanisms.

(1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid modulates GABA levels to treat tinnitus and ADHD symptoms.

Combining Ginkgolides A, B, C, J, and L in specific ratios relieves oxidative stress and improves depressive states.

Piperidinylpyridinylcarbonitrile derivatives target QPCT and QPCTL enzymes to treat lung fibrosis while maintaining metabolic stability.

Rapidly dissociating Formula I antagonists reduce motor side effects and metabolic disorders while maintaining antipsychotic efficacy.